#1 Clinical Trials Search in Europe

Iodine (123I) Iobenguane

Iodine (123I) Iobenguane, also known as 123I-MIBG, is a radioactive tracer used in medical imaging. This article explores recent clinical trials investigating its use in diagnosing and monitoring neuroblastoma, a type of childhood cancer, and cardiac transthyretin amyloidosis, a heart condition. These studies aim to compare 123I-MIBG with newer imaging techniques and assess its effectiveness in different patient populations.

Table of Contents

What is IODINE (123I) IOBENGUANE?

IODINE (123I) IOBENGUANE, also known as Iobenguane I 123 or Iobenguane (123I), is a radioactive substance used for diagnostic imaging in medicine[1]. It belongs to a class of drugs called radiopharmaceuticals, which are used to help diagnose certain medical conditions using special imaging techniques.

Uses and Applications

IODINE (123I) IOBENGUANE is primarily used in two main areas:

  1. Diagnosis and monitoring of neuroblastoma, a type of cancer that commonly affects children
  2. Assessment of cardiac conditions, particularly in patients with heart problems related to protein buildup (amyloidosis)

Neuroblastoma Diagnosis

IODINE (123I) IOBENGUANE plays a crucial role in the diagnosis and monitoring of neuroblastoma[1]. Neuroblastoma is a cancer that develops from immature nerve cells and most commonly affects children. The diagnostic process using this substance involves:

  • Imaging technique: The substance is used in a type of scan called SPECT-CT (Single Photon Emission Computed Tomography combined with Computed Tomography).
  • Detection of cancer cells: IODINE (123I) IOBENGUANE can help identify both skeletal (bone) and soft tissue lesions in patients with neuroblastoma.
  • Monitoring: It’s used not only for initial diagnosis but also for follow-up scans to track the progress of the disease and effectiveness of treatment.

Cardiac Amyloidosis Assessment

Another important application of IODINE (123I) IOBENGUANE is in the assessment of cardiac conditions, particularly a condition called transthyretin amyloid cardiomyopathy (ATTR-CM)[2]. This is a heart condition where a protein called transthyretin builds up in the heart, affecting its function. The use of this substance in cardiac imaging helps in:

  • Evaluating heart function: It can provide information about the autonomic nervous system of the heart, which controls heart rate and other involuntary functions.
  • Monitoring treatment effectiveness: It’s used to assess how well treatments for ATTR-CM are working over time.
  • Comparing disease stages: The uptake of IODINE (123I) IOBENGUANE can be compared between early and progressive stages of the disease.

Administration and Procedure

The administration of IODINE (123I) IOBENGUANE typically involves the following steps[2]:

  1. Injection: The substance is usually given as an intravenous injection or infusion.
  2. Imaging: After injection, specialized cameras are used to capture images of the body.
  3. Duration: The entire procedure, including preparation and image acquisition, can take several hours.

Safety and Considerations

While IODINE (123I) IOBENGUANE is generally considered safe, there are some important considerations[1][2][3]:

  • Radiation exposure: As a radioactive substance, it involves some radiation exposure. However, the levels are carefully controlled and monitored.
  • Pregnancy and breastfeeding: It’s not recommended for use in pregnant or breastfeeding women.
  • Age restrictions: For neuroblastoma diagnosis, it’s used in children, while for cardiac imaging, it’s typically used in adults over 40.
  • Medical history: Patients with certain conditions like Parkinson’s disease or insulin-dependent diabetes may not be suitable candidates for this imaging technique.
  • Medication interactions: Some medications, particularly certain antidepressants and heart medications, may interfere with the imaging results.

Ongoing Research

Researchers are continually working to improve diagnostic techniques for conditions like neuroblastoma and cardiac amyloidosis. Some ongoing studies are[1][3]:

  • Comparing IODINE (123I) IOBENGUANE with newer imaging agents like [18F]mFBG for neuroblastoma detection.
  • Investigating the use of IODINE (123I) IOBENGUANE alongside other imaging techniques like MRI and PET scans for more comprehensive disease assessment.
  • Studying the safety and effectiveness of these imaging techniques in pediatric populations.

These ongoing research efforts aim to enhance our ability to diagnose and monitor these complex conditions, potentially leading to better patient outcomes in the future.

Aspect Details
Primary Use Diagnostic imaging for neuroblastoma and cardiac transthyretin amyloidosis
Comparison Studies 123I-MIBG vs. 18F-mFBG PET-CT for neuroblastoma detection
Patient Populations Children with suspected or known neuroblastoma; Adults with transthyretin amyloid cardiomyopathy
Safety Assessment Short-term safety and tolerability in pediatric patients
Cardiac Applications Quantification of cardiac autonomic function in ATTR-CM
Research Objectives Compare diagnostic performance, establish reference values, assess interobserver agreement, calculate radiation doses

FAQ

  • What is Iodine (123I) Iobenguane used for in clinical trials? Iodine (123I) Iobenguane, also called 123I-MIBG, is being used in clinical trials primarily for diagnostic imaging. It's being studied for detecting neuroblastoma in children and assessing cardiac function in patients with transthyretin amyloid cardiomyopathy.
  • How does 123I-MIBG compare to newer imaging techniques? Clinical trials are comparing 123I-MIBG SPECT-CT scans to newer techniques like 18F-mFBG PET-CT for neuroblastoma detection. These studies aim to determine if the newer methods can provide better or comparable diagnostic performance in detecting skeletal and soft tissue lesions.
  • Is 123I-MIBG safe for use in children? While 123I-MIBG is being used in pediatric patients, one of the clinical trials is specifically assessing its short-term safety and tolerability in children with neuroblastoma. This study will help provide more information about its safety profile in young patients.
  • What are researchers hoping to learn from these clinical trials? Researchers are aiming to compare the effectiveness of 123I-MIBG to newer imaging techniques, establish reference values for uptake in different tissues, assess interobserver agreement in lesion detection, and calculate radiation doses in various organs and tumors.
  • How is 123I-MIBG being used in heart-related studies? In cardiac studies, 123I-MIBG is being used to assess cardiac autonomic function in patients with transthyretin amyloid cardiomyopathy. The research aims to quantify and compare 123I-MIBG uptake in different stages of the disease and evaluate changes after treatment with tafamidis.

Ongoing Clinical Trials on Iodine (123I) Iobenguane

  • Study Comparing [18F]meta-fluorobenzylguanidine PET-CT and Iodine (123I) Iobenguane Scans for Detecting Neuroblastoma in Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Heart Amyloidosis Using Sodium Fluoride (18F) and Iodine (123I) Iobenguane for Patients with Transthyretin Amyloid Cardiomyopathy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Neuroblastoma: A type of cancer that develops from immature nerve cells, most commonly occurring in children.
  • SPECT-CT: Single-Photon Emission Computed Tomography combined with Computed Tomography, an imaging technique that provides both functional and anatomical information.
  • PET-CT: Positron Emission Tomography combined with Computed Tomography, an imaging technique that provides detailed information about both the structure and function of cells and tissues in the body.
  • Transthyretin amyloid cardiomyopathy (ATTR-CM): A heart condition caused by the buildup of abnormal proteins (amyloids) in the heart muscle, affecting its function.
  • Tafamidis: A medication used to treat transthyretin amyloid cardiomyopathy by stabilizing the transthyretin protein and slowing the progression of the disease.
  • SUVmean and SUVmax: Standardized Uptake Values (mean and maximum) used to measure the intensity of tracer uptake in medical imaging.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria used for the standardized classification of adverse effects of drugs in clinical trials.
  • Myocardial microcalcification: Tiny deposits of calcium in the heart muscle, which can be a sign of heart disease.
  • Global longitudinal strain: A measure of the heart's ability to contract, used to assess heart function.
  • NT-ProBNP: N-terminal pro-brain natriuretic peptide, a blood marker used to assess heart failure and cardiac function.

References

  1. http://clinicaltrials.eu/trial/study-comparing-18fmeta-fluorobenzylguanidine-pet-ct-and-iodine-123i-iobenguane-scans-for-detecting-neuroblastoma-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-heart-amyloidosis-using-sodium-fluoride-18f-and-iodine-123i-iobenguane-for-patients-with-transthyretin-amyloid-cardiomyopathy/
  3. http://clinicaltrials.eu/trial/study-on-the-safety-of-68ga-sato-and-iodine-123i-iobenguane-in-children-with-neuroblastoma/